1 week Ago By ABMN Staff
AtriCure, Inc. ( NASDAQ:ATRC – Get Free Report ) has earned an average rating of “Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating.
The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $42.44. ATRC has been the topic of a number of research analyst reports.
JPMorgan Chase & Co. dropped their price target on shares of AtriCure from $34.00 to $30.
00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. BTIG Research reduced their price target on AtriCure from $58.00 to $53.
00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Stifel Nicolaus cut their price objective on AtriCure from $30.00 to $26.
00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Piper Sandler dropped their target price on AtriCure from $65.00 to $40.
00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Finally, Needham & Company LLC dropped their target price on AtriCure from $40.00 to $34.
00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. View Our Latest Stock Report on AtriCure AtriCure Stock Performance AtriCure ( NASDAQ:ATRC – Get Free Report ) last issued its quarterly earnings data on Tuesday, July 30th. The medical device company reported ($0.
17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of $116.
27 million for the quarter, compared to analysts’ expectations of $116.24 million. AtriCure had a negative net margin of 9.
33% and a negative return on equity of 8.39%. The business’s revenue was up 15.
2% on a year-over-year basis. During the same quarter last year, the company earned ($0.12) EPS.
Sell-side analysts expect that AtriCure will post -0.77 EPS for the current year. Insider Buying and Selling In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, August 15th.
The stock was sold at an average price of $24.07, for a total value of $84,245.00.
Following the completion of the sale, the director now owns 8,970 shares in the company, valued at $215,907.90. The sale was disclosed in a document filed with the SEC, which is available through this link .
3.20% of the stock is owned by company insiders. Institutional Investors Weigh In On AtriCure Several large investors have recently modified their holdings of ATRC.
Hood River Capital Management LLC acquired a new position in AtriCure during the second quarter worth $40,422,000. First Light Asset Management LLC lifted its position in AtriCure by 42.1% during the second quarter.
First Light Asset Management LLC now owns 1,964,703 shares of the medical device company’s stock worth $44,736,000 after buying an additional 581,843 shares during the period. Champlain Investment Partners LLC lifted its position in AtriCure by 27.3% during the first quarter.
Champlain Investment Partners LLC now owns 2,681,000 shares of the medical device company’s stock worth $81,556,000 after buying an additional 575,605 shares during the period. Millennium Management LLC raised its holdings in shares of AtriCure by 132.5% in the 2nd quarter.
Millennium Management LLC now owns 952,765 shares of the medical device company’s stock worth $21,694,000 after purchasing an additional 543,023 shares during the period. Finally, Natixis purchased a new position in shares of AtriCure in the 1st quarter worth about $9,126,000. Hedge funds and other institutional investors own 99.
11% of the company’s stock. About AtriCure ( Get Free Report AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
Read More Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter ..
